SinoMab BioScience EPS
What is the EPS of SinoMab BioScience?
The EPS of SinoMab BioScience Limited is -0.16
What is the definition of EPS?
Earnings per share (EPS) is the portion of a company’s profit allocated to each outstanding share of common stock. It is adjusted for dilution and calculated over trailing twelve months.
ttm (trailing twelve months)
Earnings per share is the monetary value of earnings per outstanding share of common stock for a company. Preferred stock rights have precedence over common stock. Therefore, dividends on preferred shares are subtracted before calculating the EPS. When preferred shares are cumulative, annual dividends are deducted whether or not they have been declared. Dividends in arrears are not relevant when calculating EPS. The EPS is usually calculated as profit without preferred dividends divided by weighted average of common stock shares over the past twelve months.
EPS of companies in the Health Care sector on HKSE compared to SinoMab BioScience
What does SinoMab BioScience do?
SinoMab BioScience Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of therapeutics for the treatment of immunological diseases, primarily monoclonal antibody (mAb)-based biologics. Its flagship product is SM03, a first-in-target anti-CD22 mAb, which is in Phase III clinical trial for the treatment of rheumatoid arthritis (RA), as well as in various clinical stages for other immunological diseases, such as systemic lupus erythematosus (SLE), Sjogren's syndrome (SS), and non-Hodgkin's lymphoma (NHL). The company also focuses on developing SN1011, a Bruton's tyrosine kinase inhibitor, which is Phase I clinical trial for the treatment of RA, SLE, pemphigus, multiple sclerosis, and other immunological diseases. Its products under preclinical stage comprise SM17 for the treatment of asthma and idiopathic pulmonary fibrosis; SM09 that is used for the treatment of NHL and RA; SM06 for use in treating RA, SLE, and SS; and TNF2 for the treatment of RA. The company operates in Mainland China, the Cayman Islands, and Hong Kong. SinoMab BioScience Limited was incorporated in 2001 and is headquartered in Pak Shek Kok, Hong Kong.
Companies with eps similar to SinoMab BioScience
- Taizhou Water Co has EPS of -0.16
- Jiangsu Jingyuan Environmental Protection Co has EPS of -0.16
- Venus Medtech (Hangzhou) Inc has EPS of -0.16
- Hive Blockchain Technologies has EPS of -0.16
- Honworld has EPS of -0.16
- TUS International has EPS of -0.16
- SinoMab BioScience has EPS of -0.16
- Emerita Resources has EPS of -0.16
- Tiziana Life Sciences Plc has EPS of -0.16
- Interbit has EPS of -0.16
- Accuray has EPS of -0.15
- Mercator has EPS of -0.15
- Century City International has EPS of -0.15